Experian is exiting the financial data technology provider Finicity in a deal that could reach $985m taking earn-outs into account.

Celgene Switzerland and BMS-backed precision cancer drug developer Repare Therapeutics added $33m to its IPO after its shares rose 65% post-offering.

The Salesforce-backed banking platform developer has filed for a $100m initial public offering having raised $80m late last year.

The IoT security technology provider had raised $48m in funding from investors including Qualcomm and Čez pre-acquisition.

Equifax was among the investors that provided $14.7m for the utility customer data provider to push its total funding past the $40m mark.

MemorialCare Innovation Fund contributed to a series D round that brought the heart valve technology developer's overall funding to more than $36m.

The Qiagen-founded precision cancer technology provider agreed to an acquisition by Invitae sized at at least $325m in cash and shares currently valued at about $820m.

Novartis is the second largest investor in the gene therapy developer, which has filed to go public less than a year after closing a $150m round.

The series C round consisted of $77m in equity funding and $25m in venture debt, with Kaiser Permanente among the participants.

Hartford Healthcare returned for a $50m series C round that will support the Stanford spinout in advancing potential treatments for severe liver and inflammatory bowel diseases.